A federal jury in Delaware put US biotech major Amgen (Nasdaq: AMGN) on the hook Thursday for at least $271.2 million in ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market Jury awarded ...

The uptake of novel lipid‐lowering therapy (LLT) has been low; however, variations in clinician prescribing patterns have not been well studied. This study sought to describe early prescribing ...

Regeneron Pharmaceuticals, Inc. announced that it will present new and updated data from its oncology and hematology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced financial results for the first quarter of 2025 and provided a business update. "We have ...

Regeneron (REGN) reported $3.03 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3.7%. EPS of $8.22 for the same period compares to $9.55 a year ago. The ...

Patients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy. In the FOURIER trial (Further Cardiovascular Outcomes Research ...

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has ...